Pancreatic adenocarcinoma is a highly aggressive malignancy with a poor prognosis
secondary to late presentation with metastases, challenging resection, and limited …

Background Hepatopancreaticobiliary (HPB) diseases carry high morbidity despite efforts
aimed at their reduction. An assessment of their trial characteristics is paramount to …

Die Resektion stellt die einzige kurative Therapieoption beim Adenokarzinom des Pankreas
dar. Das Rezidivrisiko nach Resektion ist allerdings hoch, sodass in den vergangenen 20 …

Pancreatic adenocarcinoma is one of the most lethal cancers in oncology. Pancreatic cancer
is the third most common cause of cancer-related mortality in the United States. As the years …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival. Local
control through surgical resection paired with radiotherapy and chemotherapy comprise the …

Die Mehrzahl der Patienten mit Pankreaskarzinom leidet unter einer Mangelernährung, die
sich als Sarkopenie und/oder Tumorkachexie manifestiert. Diese Mangelernährung schränkt …

Neoadjuvant Treatment (NAT) is indicated in locally advanced tumors and improves the
results of subsequent surgery. In borderline tumors, the place of this preoperative treatment …

Neoadjuvant therapy (NAT) is an emerging strategy for treating potentially resectable
pancreatic adenocarcinoma (PA). Although a strong rationale and many theoretical …

Achieving an R0-resection is a prerequisite for long-term survival in pancreatic cancer.
Preoperative therapy may downstage locally advanced and borderline pancreatic cancer …

Identifying early-stage cancer patients at risk for progression is a major goal of biomarker
research. This report describes a novel 19-gene signature (19-GCS) that predicts stage I …